Physician profile
David Tom
NPI 1437184298
$1,709.74
in general payments reported to CMS, 2019-2025
11 companies · $69.12 in 2025
The $69.12 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $92.30 · 2021: $191 · 2022: $257 · 2023: $259 · 2024: $179 · 2025: $69.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $543.44 | 2019-2024 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $318.23 | 2019-2020 | |
| Genentech USA, INC. | $314.83 | 2019-2025 | Vabysmo |
| Alcon Vision LLC | $148.15 | 2019 | |
| Mallinckrodt Hospital Products INC. | $107.58 | 2021 | |
| Abbvie INC. | $101.42 | 2023-2025 | Ozurdex |
| Coherus Oncology, INC. | $71.37 | 2023 | |
| Allergan, INC. | $50.45 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.27 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb Americas INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.